Woman reading the Dagens Industri newspaper

Press releases

Category
Year

Oncopeptides announces final terms for the fully guaranteed rights issue Regulatory

April 8, 2024
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT
Read more

Oncopeptides releases first quarter 2024 sales Regulatory

April 4, 2024
Stockholm – April 4, 2024 – Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the unaudited net sales for the first quarter of 2024
Read more

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

March 27, 2024
Stockholm, Sweden and Dubai, UAE, March 27, 2024 – Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq
Read more

Extraordinary General Meeting in Oncopeptides AB (publ) Regulatory

March 13, 2024
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, SE-111 53 Stockholm, Sweden on Monday 15 April 2024 at 15:00 CEST. Registration for attendees will commence at 14:30 CEST
Read more

Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026 Regulatory

March 13, 2024
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT
Read more

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration

March 1, 2024
Stockholm – March 1, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma & Leukemia. The results provide further evidence that administration via peripheral venous catheter (PVC) is well tolerated with no local infusion-related reactions or new safety signals and may represent an alternative route of administration
Read more

Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica

February 29, 2024
Stockholm – February 29, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica, a monthly peer-reviewed open access medical journal
Read more

Oncopeptides publishes year-end report 2023 Regulatory

February 27, 2024
Stockholm – February 27, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2023
Read more

Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market

February 23, 2024
Stockholm – February 23, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed
Read more

Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority Regulatory

February 23, 2024
Stockholm, February 23, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti
Read more